T hrombolytic treatment with alte plase, a recombinant tissue plasminogen activator, for acute ischemic stroke is of proven benefit. 1 However, alteplase is far from ideal, with incomplete and often delayed reperfu sion in many patients. 2 Tenecteplase, a genetically engineered mutant tissue plasminogen activator, has some pharmacokinetic advantages over alte plase. 3 A balance between efficacy and risk of bleeding in the treatment of stroke appears to be achieved at a lower dose of tenecteplase than the dose used for myocardial infarction. 4 A recent dose ranging study of tenecteplase involving patients with acute ischemic stroke, which used standard clinical selection criteria, showed that a dose of 0.4 mg per kilogram of body weight was associ ated with excess intracranial hemorrhage. The trial was stopped prematurely, owing to slow enroll ment, with no difference shown between doses of 0.1 mg per kilogram and 0.25 mg per kilogram. 5 In a nonrandomized pilot trial, we found that patients who received tenecteplase at a dose of 0.1 mg per kilogram had superior outcomes on imaging (reperfusion and infarct growth) and greater early clinical improvement than patients who received alteplase at a dose of 0.9 mg per ki logram. 6 However, only the patients who received tenecteplase were treated on the basis of computed tomographic (CT) perfusion and angiographic im aging. We conducted a phase 2B, randomized trial to compare the standard dose of alteplase with two different doses of tenecteplase. CT perfusion and angiographic imaging was used to select patients who would be the most likely to benefit from early reperfusion (i.e., patients with largevessel occlu sion and a large perfusion lesion in the absence of a large infarct core).
ME THODS

STUDY DESIGN AND PATIENTS
In this randomized, openlabel, blinded trial, pa tients with acute ischemic stroke underwent CT perfusion and angiographic imaging before receiv ing treatment with intravenous tenecteplase or alte plase, which was administered within 6 hours after the onset of the stroke. Patients underwent mag netic resonance imaging (MRI) at 24 hours and at 90 days for assessment of imaging outcomes. The trial was performed between 2008 and 2011 in three large stroke centers in Australia. The study design is shown in the Supplementary Appendix, which is available with the full text of this article at NEJM.org.
We enrolled patients with firstever hemispheric ischemic stroke who were 18 years of age or older, had a score greater than 4 on the National Insti tutes of Health Stroke Scale (NIHSS; a 42point scale that quantifies neurologic deficits in 11 cat egories, with higher scores indicating more severe deficits), and a premorbid score of 2 or less on the modified Rankin scale (which ranges from 0 to 6, with 0 indicating no symptoms and 6 indicating death) (Table 1) . Exclusion criteria were standard contraindications to alteplase. 7, 8 In addition, we used specific selection criteria for this trial that were based on the results of CT imaging. 6 The CT angiographic criterion was the presence of intracranial occlusion in the anterior cerebral, middle cerebral, or posterior cerebral ar tery. Patients with internalcarotidartery and verte brobasilar occlusions were excluded. The CT perfu sion criterion was a hemispheric perfusion lesion on transittime maps that was at least 20% great er than the infarctcore lesion, with a volume of at least 20 ml. The infarctcore lesion on CT perfu sion maps of cerebral blood volume had to be less than one third the territory of the middle cerebral artery or less than one half the territory of the anterior cerebral or posterior cerebral artery.
The review of CT images was performed at a clinical imaging workstation with the use of instrumentspecific proprietary software. The onconsole image analysis was performed by the treating stroke neurologists, all of whom had experience in the evaluation of CT perfusion and angiographic imaging. 9 Patients were randomly assigned in a 1:1:1 ratio to the standard dose of alteplase (0.9 mg per kilo gram, the first 10% administered as an initial bo lus and the remainder over a 1hour period, with a maximum dose of 90 mg) or to tenecteplase (0.1 mg per kilogram, administered as a single bolus, with a maximum dose of 10 mg; or 0.25 mg per kilogram, administered as a single bolus, with a maximum dose of 25 mg). A central block ran domization was performed by the Centre for Clinical Epidemiology and Biostatistics, University of Newcastle, in blocks of 15 to allow the data and safety monitoring board to review blinded safety data after the recruitment of every 15 patients. Randomization was performed by means of a cen tral telephone service. The treating clinician was aware of the treatment assignments.
STUDY OVERSIGHT
The steering committee, comprising five of the au thors, designed and oversaw the trial and vouches for the completeness and accuracy of the data and the analysis. The data analysis was undertaken by four of the authors. One of the authors, a biostat istician, was responsible for the unblinding of the treatment assignments after the database was cleaned and locked, and performed the prespeci fied statistical analyses. Boehringer Ingelheim sup Posterior cerebral artery 1 (4) 1 (4) 1 (4)
Terminal internal carotid artery 0 1 (4) 0 None 2 (8) 1 (4) 0 * Plus-minus values are means ±SD. Lesion volumes are rounded to the nearest milliliter. There were no significant differences between the alteplase group and the pooled tenecteplase groups except that the alteplase group had fewer people with diabetes (P = 0.01), fewer smokers (P = 0.01), and a lower mean blood glucose level (P = 0.05). To convert the values for glucose to milligrams per deciliter, divide by 0.05551. There were no significant differences in baseline characteristics between the two tenecteplase groups. † Scores on the National Institutes of Health Stroke Scale (NIHSS) range from 0 to 42; higher scores indicate more severe neurologic deficits.
The plied tenecteplase at a discount but was not in volved in the study design, study conduct, data management, data analysis, or manuscript prepa ration. Alteplase was supplied by the treating hos pital, because it is the standard treatment. Written informed consent was provided by the patients or their health care proxies. The study protocol (available at NEJM.org) and informed consent procedures were approved by the institu tional review board at each participating center.
PROCEDURES
CT perfusion and angiographic imaging was per formed with multidetector scanners (16 or 64slice) before randomization. Wholebrain CT imaging, without the administration of contrast material was followed by CT perfusion imaging, comprising two 60second series, each performed after an intrave nous bolus of 40 ml of iodinated contrast agent at a concentration of 370 mg per milliliter, followed by a 40ml saline flush at a rate of 6 ml per sec ond. 10 Each perfusion series covered an axial sec tion of 24 to 40 mm, acquired as adjacent slices of 5 to 8 mm. 11 CT angiography was performed after CT perfusion imaging, with images acquired from the carotid bifurcation to the top of the lateral ventricles.
MRI was performed with the use of 1.5T scanners. Standardized sequences were obtained 24 hours after treatment and included an axial gradientecho T 2 weighted series, a diffusion weighted echoplanar spinecho sequence, timeof flight magnetic resonance angiography, perfusion weighted imaging, and a fluidattenuated inversion recovery (FLAIR) sequence. 12, 13 At 90 days after treatment, FLAIR imaging was repeated to mea sure the final infarct volume.
OUTCOMES
The coprimary outcomes were the percentage of the perfusion lesion that was reperfused 24 hours after treatment, as assessed on perfusionweight ed MRI, and the extent of clinical improvement at 24 hours, as measured by the change on the NIHSS score from before treatment to 24 hours after treat ment. 6,14 Secondary imaging efficacy outcomes were the extent of infarct growth at 24 hours and at 90 days and vessel recanalization at 24 hours. 15, 16 Secondary clinical efficacy outcomes were ma jor neurologic improvement at 24 hours (defined as a reduction from baseline of 8 or more points on the NIHSS), excellent recovery at 90 days (de fined as a score of 0 or 1 on the modified Rankin scale), and excellent or good recovery at 90 days (defined as a score of 0 to 2). 1,7,17,18 These scores on the modified Rankin scale have been used as primary outcomes in all major phase 3 trials of thrombolytic agents: a score of 0 indicates no symptoms, 1 minor symptoms but no clinically significant disability, and 2 slight disability. 1,7,19 Secondary imaging safety outcomes were the occurrence of large parenchymal hema toma (>30% of the infarct volume), parenchymal hematoma of any size, and symptomatic intracra nial hemorrhage. Secondary clinical safety out comes were poor outcome (i.e., severe disability) or death at 90 days, defined as a score of 5 or 6, re spectively, on the modified Rankin scale. See the Supplementary Appendix for details of outcomes.
All analyses of imaging outcomes were per formed centrally on deidentified data. Assessors were unaware of the treatment assignments and clinical information. CT and MRI data were ana lyzed with the use of commercial software (MIStar, Apollo Medical Imaging). 20 See the Supplementary Appendix for details of the imaging outcomes.
Scoring on the NIHSS was performed immedi ately before baseline imaging and at 24 hours. Scoring on the modified Rankin scale was per formed at baseline and on day 90. The clinical assessments at 24 hours and on day 90 were per formed by a trained observer who was not involved in the patients' clinical care and who was unaware of the treatment assignments. The observer cal culated the patients' scores on the NIHSS or the modified Rankin scale in the presence of a study coordinator, who ensured that the observer re mained unaware of the treatment assignments.
STATISTICAL ANALYSIS
Before the completion of the study, a biostatistician developed the statistical analysis plan to test the prespecified trial hypotheses defined in the proto col. The primary hypothesis was that a comparison between the alteplase group and the pooled te necteplase groups would show the superiority of tenecteplase with respect to one or both copri mary outcomes (percent reperfusion and change in the NIHSS score at 24 hours). An alpha level of 0.025 was prespecified for each of the two pri mary end points. We calculated the sample size for the current study on the basis of our pilot study, with power set at 80% and an assumption of supe riority with respect to one of the two coprimary outcomes, at an alpha level of 0.025, in the pooled tenecteplase groups. Primary hypotheses were tested by means of an unadjusted Student's ttest of means. This analysis was repeated after adjustment for poten tial confounding baseline variables that differed between the alteplase and pooled tenecteplase groups (P<0.10) ( Table 1) . Secondary outcomes with a nonparametric distribution were tested with the use of the Wilcoxon ranksum test, and cat egorical variables were compared with the use of the chisquare test of proportions or Fisher's exact test. In the event of support for the primary hy pothesis, the protocol specified an analysis to compare efficacy and safety outcomes between the two tenecteplase groups and between each of the tenecteplase groups and the alteplase group.
After the initial trial registration but before the completion of the study, the trial end points were modified, as informed by several studies. 6, 13, 17, 20 This led to the modification of the reperfusion primary outcome from absolute volume change to proportional change. 6,13 Infarct growth replaced "mismatch salvage" (i.e., the volume of mismatch tissue on CT perfusion imaging at baseline that did not progress to infarction on followup MRI) as a secondary outcome, and the intracranial hemorrhage outcomes were expanded (see the Supplementary Appendix). The prespecified sta tistical analysis plan was based on these slightly modified end points. However, after the study and the perprotocol prespecified analyses were completed, we performed post hoc analyses of the original end points (see the Supplementary Appendix). Figure 1 shows the screening profile of the trial. Between 2008 and 2011, a total of 2768 patients presenting with strokelike symptoms underwent screening within 6 hours after symptom onset; of these patients, 75 (3%) were enrolled in the study. The majority of patients screened (2164 [78%]) were not eligible for intravenous thrombolysis on the basis of standard clinical exclusions (Fig. 1) . This left 604 patients (22%) potentially eligible for intravenous thrombolysis, 127 (5%) of whom met the additional CT selection criteria. The major reasons for exclusion that were based on these cri teria were internalcarotidartery occlusion ( Of the 2768 patients who were screened for participation in the study, 75 underwent randomization to the three treatment groups. INR denotes international normalized ratio. Of the 75 enrolled patients, 25 were randomly assigned to each of the three treatment groups. Table 1 shows the baseline characteristics of these patients. The mean (±SD) NIHSS score for all pa tients in the trial was relatively high at 14.4±2.6. Most baseline clinical characteristics were well matched among the three groups, but the alte plase group included fewer persons who smoked (P = 0.01); this group also included fewer persons with diabetes (P = 0.01), which was reflected in a lower blood glucose level at baseline in the al teplase group (P = 0.05). Patients in the alteplase group received treatment at a mean of 2.7 hours, as compared with 3.1 hours for those in the pooled tenecteplase groups (P = 0.06). Only 3 patients were treated after 4.5 hours. There were no significant differences in the imaging characteristics at base line among the treatment groups. There were no significant differences in the site of occlusion at baseline, but on central blinded review of the CT angiographic data, the vesselocclusion criteria were not met in 4 patients (Table 1) . One patient had an occlusion of the terminal internal carotid artery, and 3 patients (2 in the alteplase group) had no definite occlusion.
R E SULT S
STUDY PATIENTS
EFFICACY
There was a significant benefit associated with tenecteplase for both coprimary end points of the study (Table 2) , with greater reperfusion (P = 0.004) and greater clinical improvement (P<0.001) at 24 hours in the pooled tenecteplase groups than in the alteplase group. The magnitude and signifi cance of the reperfusion and early clinical improve ment in the pooled tenecteplase groups did not change after correction for imbalances at baseline (Table 2) . Tenecteplase was also beneficial with respect to secondary outcomes. In the pooled te necteplase groups, as compared with the alteplase group, infarct growth was reduced, and a higher proportion of patients had an excellent or good recovery (modified Rankin scale score of 0 to 2) at 90 days (72% vs. 44%, P = 0.02).
SAFETY
Seven patients died: 3 in the alteplase group (12%), 3 in the group that received the lower dose of tenecteplase (12%), and 1 in the group that re ceived the higher dose of tenecteplase (4%). Two deaths in the alteplase group were due to massive hemispheric infarction, and one to symptomatic intracranial hemorrhage. In the lowerdose tenec te plase group, one death was due to symptomatic intracranial hemorrhage, one to aspiration pneu monia, and one to a late second stroke. The one death in the higherdose tenecteplase group was due to multiple coexisting conditions (pneumonia, myocardial infarction, and acuteonchronic renal failure). Two of the 50 patients in the tenecteplase group (4%) had large parenchymal hematomas, as compared with 4 of the 25 in the alteplase group (16%, P = 0.09). Five of the 6 patients with large parenchymal hematomas also had symp tomatic deterioration of 4 or more points on the NIHSS at 24 hours and poor outcome at 90 days (modified Rankin scale score of 5 or 6). Poor outcome at 90 days occurred in 7 patients in the alteplase group (28%) and in 5 (10%) in the pooled tenec te plase groups (P = 0.09).
DOSE-TIER ANALYSIS
The higher dose of tenecteplase (0.25 mg per ki logram) was associated with improvement on all imaging efficacy outcomes, as compared with alte plase (see the Supplementary Appendix). In addition to an increased proportion of patients with early clinical improvement, the outcomes at 3 months were better in the higherdose tenec te plase group; 72% of patients in this group had an excellent recovery (no clinically significant disabil ity), as compared with 40% of those in the alte plase group (P = 0.02). There were no more adverse out comes with either dose of tenecteplase than with alteplase (see the Supplementary Appendix). The patients who received the lower dose of tenec te plase had greater clinical improvement at 24 hours than did the patients who received alteplase (P = 0.04), but other efficacy outcomes were equiv alent between the two groups.
There was an efficacy dose response between the two tenecteplase dose tiers, including higher
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Copyright © 2012 Massachusetts Medical Society. All rights reserved. and were not included in the analysis of the primary reperfusion outcome (or other imaging-based efficacy outcomes). Five patients died before day 90 and were not included in the analysis of infarct growth at day 90. Five patients were not included in the analysis of recanalization outcomes: the two who did not undergo MRI at 24 hours and the three without occlusions at baseline. † The mean percentage of reperfusion remained significant (P = 0.003) after adjustment for the baseline variables of status with respect to diabetes and smoking, blood glucose level, and time to treatment. ‡ The mean change in the NIHSS score at 24 hours remained significant (P = 0.001) after adjustment for the baseline variables of status with respect to diabetes and smoking, blood glucose level, and time to treatment. § This outcome was defined as a large parenchymal hematoma and clinical worsening (an increase in the NIHSS score of 4 or more points).
17,21,22 ¶ Recovery was assessed with the modified Rankin scale, which ranges from 0 to 6, with higher scores indicating greater disability. Excellent recovery was defined as a score of 0 or 1, excellent or good recovery as 0 to 2, and a poor outcome as 5 or 6. ‖ The mismatch salvage was defined as the volume of mismatch on computed tomographic perfusion imaging at baseline that did not progress to infarction. reperfusion and recanalization rates at the higher dose (Fig. 2 , and the Supplementary Appendix). This translated into greater clinical improvement at 24 hours and an increase in the number of pa tients with excellent recovery (no clinically signifi cant disability) at 90 days (P = 0.01).
DISCUSSION
In this study, using CT perfusion and angiograph ic imaging to select patients for thrombolytic treat ment of acute ischemic stroke, we found that te necteplase was superior to alteplase with respect to the coprimary end points of reperfusion and clinical improvement at 24 hours. It is convention al in studies of acute stroke to use a primary out come that assesses disability status at 90 days. However, reperfusion needs to be measured at a shorter interval after early reperfusion treatment in order to assess biologic efficacy, so we chose a pri mary clinical outcome that was most likely to be sensitive to early reperfusion. A longerterm clinical benefit was also seen, particularly with the higher dose of tenecteplase. The improved reperfusion and clinical response with tenecteplase did not come at a cost of increased intracranial hemorrhage. There was also a dose-response relationship, with the higher dose of tenecteplase being superior to both the lower dose of tenecteplase and alteplase for all imaging and clinical efficacy outcomes. These pos itive findings are encouraging but preliminary, ow ing to the small size of the study. The results of this study suggest that it is ap propriate to proceed to a phase 3 trial of tenec te plase versus alteplase in the time window that is currently approved for stroke thrombolysis. We believe that the dose response seen in the current study provides sufficient justification to use tenec te plase at a dose of 0.25 mg per kilogram as the comparator. However, for this phase 2B trial, we used criteria based on CT perfusion and angio graphic imaging to select patients for inclusion who would be most likely to have a clinical benefit from early and effective reperfusion. These selec tion criteria enhanced the power of the study to detect a difference in efficacy between tenec te plase and alteplase with the use of a relatively small sample. A large number of patients who were eligible for thrombolysis on the basis of stan dard clinical and noncontrast CT criteria were ex cluded from this trial because of these additional imaging selection requirements. We therefore can not extrapolate our results to the majority of pa tients who are eligible for thrombolysis. A phase 3 study would be needed to determine whether the efficacy of tenecteplase extends to this broader population of patients. 
